These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7997805)

  • 1. Serum markers CASA and CA 15-3 in ovarian cancer: all MUC1 assays are not the same.
    Devine PL; McGuckin MA; Quin RJ; Ward BG
    Tumour Biol; 1994; 15(6):337-44. PubMed ID: 7997805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of mucin-specific monoclonal antibodies and lectins in the detection of tumor-associated serum markers in gynecological cancer.
    Devine PL; McGuckin MA; Ramm LE; Harada H; Ward BG
    Cancer Biochem Biophys; 1993 Sep; 13(4):221-38. PubMed ID: 8521372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
    Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
    Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors effecting the measurement of tumor-associated MUC1 mucins in serum.
    McGuckin MA; Devine PL; Ramm LE; Ward BG
    Tumour Biol; 1994; 15(1):33-44. PubMed ID: 8146528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
    Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
    Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of tetranectin, CA-125 and CASA to predict residual tumor and survival at second- and third-look operations for ovarian cancer.
    Høgdall CK; Høgdall EV; Hørding U; Toftager-Larsen K; Arends J; Nørgaard-Pedersen B; Clemmensen I
    Acta Oncol; 1996; 35(1):63-9. PubMed ID: 8619942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumour-associated mucin concentrations, determined by the CASA assay, in healthy women.
    McGuckin MA; Ramm LE; Joy GJ; Devine PL; Ward BG
    Clin Chim Acta; 1993 Feb; 214(2):139-51. PubMed ID: 8472380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
    Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer.
    Devine PL; Duroux MA; Quin RJ; McGuckin MA; Joy GJ; Ward BG; Pollard CW
    Breast Cancer Res Treat; 1995 Jun; 34(3):245-51. PubMed ID: 7579489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer.
    Kierkegaard O; Mogensen O; Mogensen B; Jakobsen A
    Gynecol Oncol; 1995 Nov; 59(2):251-4. PubMed ID: 7590482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevation of multiple serum markers in patients with stage I ovarian cancer.
    Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
    J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
    Oehler MK; Sütterlin M; Caffier H
    Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coordinate elevation of serum markers in ovarian cancer but not in benign disease.
    Bast RC; Knauf S; Epenetos A; Dhokia B; Daly L; Tanner M; Soper J; Creasman W; Gall S; Knapp RC
    Cancer; 1991 Oct; 68(8):1758-63. PubMed ID: 1913520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serological pancreatic tumor markers and the MUC1 apomucin.
    Ho JJ; Kim YS
    Pancreas; 1994 Nov; 9(6):674-91. PubMed ID: 7846010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women.
    Richards ER; Devine PL; Quin RJ; Fontenot JD; Ward BG; McGuckin MA
    Cancer Immunol Immunother; 1998 Jul; 46(5):245-52. PubMed ID: 9690452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The management of ovarian carcinoma is improved by the use of cancer-associated serum antigen and CA 125 assays.
    Ward BG; McGuckin MA; Ramm LE; Coglan M; Sanderson B; Tripcony L; Free KE
    Cancer; 1993 Jan; 71(2):430-8. PubMed ID: 8422635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of the human milk fat globule membrane antigen HMFG2 in epithelial ovarian cancer monitoring: comparison with CA125.
    Fisken J; Roulston JE; Sturgeon C; Badley RA; Jönrup I; Aspinall L; Leonard RC
    Br J Cancer; 1993 May; 67(5):1065-70. PubMed ID: 8494699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of serum CASA and CA 125 levels in patients with ovarian carcinoma.
    Meisel M; Straube W; Weise J; Burkhardt B
    Arch Gynecol Obstet; 1995; 256(1):9-15. PubMed ID: 7726659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of five serum marker assays in patients with advanced breast cancer treated with medroxyprogesterone acetate.
    Murray A; Clinton O; Earl H; Price M; Moore A
    Eur J Cancer; 1995 Sep; 31A(10):1605-10. PubMed ID: 7488409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer.
    Onsrud M; Shabana A; Austgulen R
    Tumour Biol; 1996; 17(2):90-6. PubMed ID: 8658018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.